Aspirin may benefit prostate cancer patients
September 5th 2012Anticoagulant therapy, particularly the use of aspirin, may reduce the risk of prostate cancer-specific mortality in men treated with radical prostatectomy or radiotherapy for prostate cancer, according to a study published online August 27 in the Journal of Clinical Oncology.
Consumers should consult pharmacists or doctors before starting a new diet
September 5th 2012New programs for casual dieters could result in nutritional deficiencies and adversely interact with medications, so consumers should consult their pharmacists or physicians before trying a new diet plan, according to the American Pharmacists Association.
New anticancer agents may lead to greater toxicity, discontinuation rates than standard therapy
September 4th 2012New anticancer agents that offer improved efficacy compared with standard therapy also increase morbidity and treatment-related mortality, according to a meta-analysis published August 20 in the Journal of Clinical Oncology.
FDA approves new treatment for a type of late-stage prostate cancer
August 31st 2012FDA approved enzalutamide (Xtandi, Astellas Pharma U.S. Inc. and Medivation) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.
FDA recommends against use of Revatio in children with pulmonary hypertension
August 31st 2012FDA issued a Drug Safety Communication on sildenafil (Revatio, Pfizer), following the observation in a long-term extension of a clinical trial in pediatric patients with pulmonary arterial hypertension of an increase in mortality with increasing Revatio dose.
FDA approves tapentadol ER for neuropathic pain associated with DPN
August 29th 2012FDA has approved the supplemental New Drug Application for tapentadol extended-release tablets (Nucynta ER, Janssen), an oral analgesic taken twice daily, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
Use of ALBC implants may lead to kidney injury
August 23rd 2012Aminoglycoside-loaded bone cement implants, frequently used in orthopedic surgery, may result in systemic effects that raise aminoglycoside serum concentrations and lead to acute kidney injury, according to a study published July 3 in The Annals of Pharmacotherapy.